Kristina Mignon Wright was appointed as Director at Centessa Pharmaceuticals plc.
“Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.”
Centessa Pharmaceuticals plc — fact timeline
Source-grounded facts extracted from Centessa Pharmaceuticals plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christopher Stokes was appointed as Director at Centessa Pharmaceuticals plc.
“Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.”
Brett Zbar departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Carol Stuckley departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Samarth Kulkarni departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Mathias Hukkelhoven departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Mary Lynne Hedley departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Arjun Goyal departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Francesco De Rubertis departed as Director at Centessa Pharmaceuticals plc.
“each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa”
Raphael Deferiere departed as Executive Officer at Centessa Pharmaceuticals plc.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
Stephen Kanes departed as Executive Officer at Centessa Pharmaceuticals plc.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
John Crowley departed as Executive Officer at Centessa Pharmaceuticals plc.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
Mario Alberto Accardi departed as Chief Executive Officer and Director at Centessa Pharmaceuticals plc.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
Centessa Pharmaceuticals plc entered into Transaction Agreement with Eli Lilly and Company and LDH XV Corporation (effective 2026-03-31).
“On March 31, 2026, Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (the “Company”), entered into a Transaction Agreement (the “Transaction Agreement”) with Eli Lilly and Company, an Indiana corporation (“Parent”), and LDH XV Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”).”
John Crowley changed role as Chief Financial Officer at Centessa Pharmaceuticals plc.
“Mr. Deferiere assumes the designation of principal accounting officer from John Crowley, who continues in his capacity as Chief Financial Officer and the Company’s principal financial officer.”
Raphael Deferiere was appointed as Chief Accounting Officer at Centessa Pharmaceuticals plc.
“On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025.”
Gregory Weinhoff was appointed as Chief Business Officer at Centessa Pharmaceuticals plc.
“On June 10, 2024, the Company also announced that the Board has appointed Dr. Gregory Weinhoff as the Company’s Chief Business Officer, on June 5, 2024, effective on the Start Date.”
John Crowley was appointed as Chief Financial Officer at Centessa Pharmaceuticals plc.
“On June 10, 2024, Centessa Pharmaceuticals plc (the “Company”) announced the appointment of John Crowley as Chief Financial Officer, which was approved by the Board of Directors of the Company on June 5, 2024, effective June 10, 2024 (the “Start Date”).”
Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2024 results: net income $38.0 million.
“Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2024”
Centessa Pharmaceuticals plc entered into "Underwriting Agreement" with Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives of the underwriters named therein (effective 2024-04-23).
“On April 23, 2024, Centessa Pharmaceuticals plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 10,810,810 American Depositary Shares (the “ADSs”), each presenting one ordinary share, with a nominal value £0.002 per share (the “Ordinary Share”), of the Company (the “Firm ADSs”), at a price to the public of $9.25 per ADS (the “Offering”).”
Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2023.
“Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended December 31, 2023.”
Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2023 results: net income $38.6 million.
“Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2023.”
Centessa Pharmaceuticals plc reported for the second quarter ended June 30, 2023 results: net income $24.9 million.
“Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended June 30, 2023.”
Centessa Pharmaceuticals plc shareholders approved Advisory approval of UK statutory directors' remuneration report for FY2022 at the 2023-06-22 meeting.
“To receive and approve, on an advisory basis, the Company’s U.K. statutory directors’ remuneration report for the financial year ended December 31, 2022. 73,897,670 264,635 32,239 —”
Centessa Pharmaceuticals plc shareholders approved Receive and adopt UK statutory annual accounts and reports for FY2022; note no dividend recommended at the 2023-06-22 meeting.
“To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2022 and to note that the Company’s directors do not recommend the payment of any dividend for the financial year ended December 31, 2022. 74,160,295 2,220 32,029 —”
Centessa Pharmaceuticals plc shareholders approved Authorization for Audit Committee to determine auditors' remuneration at the 2023-06-22 meeting.
“To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the financial year ending December 31, 2023. 74,160,344 1,954 32,246 —”
Centessa Pharmaceuticals plc shareholders approved Ratification of re-appointment of KPMG LLP (Delaware) as independent registered public accounting firm at the 2023-06-22 meeting.
“To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company’s independent registered public accounting firm, for the financial year ending December 31, 2023. 74,161,945 1,450 31,149 —”
Centessa Pharmaceuticals plc shareholders approved Re-appointment of KPMG LLP (UK) as UK statutory auditors at the 2023-06-22 meeting.
“To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company’s annual accounts and reports are laid before the Company. 74,152,822 10,473 31,249 —”
Centessa Pharmaceuticals plc shareholders approved Reappointment of directors retiring by rotation at the 2023-06-22 meeting.
“To re-appoint as a director Carol Stuckley, M.B.A., who retires by rotation in accordance with the Company’s articles of association. 73,869,967 243,946 80,631 —”
Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2023 results: net income Net Loss Attributable to Ordinary Shareholders: $50.7 million.
“Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2023.”
Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2022.
“On March 30, 2023, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended December 31, 2022.”
Centessa Pharmaceuticals plc entered into Sales Agreement with SVB Securities LLC valued at up to $125 million (effective 2023-01-27).
“On January 27, 2023, Centessa Pharmaceuticals plc (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB Securities”) with respect to an at-the-market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as the Company’s sales agent, up to $125 million of the Company’s American Depositary Shares”
Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2022 results: net income $53.9 million.
“Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2022.”
Antoine Yver changed role as Chief Medical Officer at Centessa Pharmaceuticals plc.
“Antoine Yver, M.D., M.Sc., Chairman of Development of the Company, will assume all responsibilities currently held by Dr. Shahidi effective October 14, 2022.”
Javad Shahidi departed as Chief Medical Officer at Centessa Pharmaceuticals plc.
“On October 13, 2022, Centessa Pharmaceuticals plc (the “Company”) and Javad Shahidi, M.D., M.Sc., Chief Medical Officer, mutually agreed that Dr. Shahidi will be departing from the Company.”
Gregory Weinhoff changed role as Chief Financial Officer at Centessa Pharmaceuticals plc.
“Effective as of July 31, 2022, Gregory Weinhoff, M.D., M.B.A., the Company’s Chief Financial Officer, will assume the duties and responsibilities of the Company’s principal accounting officer, in addition to the Company’s principal financial officer.”
Marella Thorell resigned as Chief Accounting Officer at Centessa Pharmaceuticals plc.
“On July 1, 2022, Marella Thorell notified Centessa Pharmaceuticals plc (the “Company”) of her decision to resign her position as the Company’s Chief Accounting Officer, and its principal accounting officer, effective as of July 31, 2022 to pursue another professional opportunity.”
Mathias Hukkelhoven was appointed as director at Centessa Pharmaceuticals plc.
“On July 1, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Mathias Hukkelhoven, Ph.D. to join the Board, effective immediately.”
Aaron Kantoff resigned as director at Centessa Pharmaceuticals plc.
“On July 1, 2022, Aaron Kantoff, a member of the board of directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company”) , notified the Company of his resignation from the Board, effective immediately.”
Robert M. Califf, M.D. resigned as Director at Centessa Pharmaceuticals plc.
“On February 16, 2022, Robert M. Califf, M.D., a member of the Board of Directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company” or “Centessa”), notified the Company of his resignation from the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.